The P2X7 Receptor: A Promising Pharmacological Target in Diabetic Retinopathy |
| |
Authors: | Matteo Tassetto Anna Scialdone Anna Solini Francesco Di Virgilio |
| |
Affiliation: | 1.Medical Residency Program in Clinical Pathology, Department of Medical Sciences, University of Ferrara, 44121 Ferrara, Italy; (M.T.); (A.S.);2.Department of Surgical, Medical, Molecular and Critical Area Pathology, University of Pisa, 56126 Pisa, Italy;3.Department of Medical Sciences, University of Ferrara, 44121 Ferrara, Italy |
| |
Abstract: | Diabetes is a worldwide emergency. Its chronic complications impose a heavy burden on patients, health systems, and on society as a whole. Diabetic retinopathy is one of the most common and serious complications of diabetes, and an established risk factor for blindness in adults. Over 15 years of investigation led to the identification of vascular endothelial growth factor (VEGF) as a main pathogenic factor in diabetic retinopathy and to the introduction of highly effective anti-VEGF-based therapies, such as the monoclonal antibody bevacizumab or its fragment ranibizumab, which helped to prevent diabetes-related blindness in millions of patients. Recently, a pathogenic role for uncontrolled increases in the extracellular ATP concentration (eATP) and for overactivation of the purinergic receptor P2X7 (P2X7R) has been suggested. The P2X7R is an eATP-gated plasma membrane channel expressed in multiple tissues and organs, with a pleiotropic function in inflammation, immunity, cancer, and hormone and growth factor release. P2X7R stimulation or overexpression positively regulate the secretion and buildup of VEGF, thus promoting neo-angiogenesis in a wide variety of disease processes. In this review, we explore current evidence that supports the role of P2X7R receptor signaling in the pathogenesis of diabetic retinopathy, as well as the most appealing current therapeutical options for P2X7R targeting. |
| |
Keywords: | diabetic retinopathy P2X7 inflammation angiogenesis neural damage |
|
|